{"schema_version":"secwatch.filing_event.v1","accession":"0001606498-24-000016","form_type":"8-K","ticker":"AVNS","cik":"0001606498","company_name":"AVANOS MEDICAL, INC.","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.791535+00:00","generated_at":"2026-06-05T23:07:24.904162+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Avanos Medical Q4 net sales $173.3M (-4.6% YoY); 2024 outlook $685-$705M revenue, adj. EPS $1.30-$1.45","bullets":["Q4 net sales $173.3M (-4.6% YoY); full-year net sales $673.3M (-1.6%) on lower HA sales.","Q4 GAAP diluted EPS $0.24 (vs $0.21); adjusted EPS $0.36 (vs $0.45). Full-year GAAP loss $(0.21) (vs $0.46 EPS); adjusted EPS $1.03 (vs $1.00).","Free cash flow for 2023 was $14.6M, down from $71.6M in 2022; Q4 outflow $3.4M.","Completed sale of respiratory health business (Oct 2) and acquired Diros Technology (July 24) to focus on Pain Management and Digestive Health.","2024 guidance: net sales $685-$705M (organic growth 3%-6%), adj. gross margin 59.5%-60.5%, adj. diluted EPS $1.30-$1.45."],"urls":{"canonical":"https://secwatch.observer/filing/0001606498-24-000016","json":"https://secwatch.observer/filing/0001606498-24-000016.json","markdown":"https://secwatch.observer/filing/0001606498-24-000016.md","text":"https://secwatch.observer/filing/0001606498-24-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606498/000160649824000016/0001606498-24-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606498/000160649824000016/avns-20240220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T23:07:24.904162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b3eb95efd3a463afc3ba136e78079316a61824a3","claim":"AVANOS MEDICAL, INC. reported fourth quarter and full-year 2023 results: revenue Fourth quarter net sales from continuing operations totaled $173.3 million, a 4.6% decrease from the prior year. For the, EPS Fourth quarter diluted earnings per share from continuing operations were $0.24 compared to diluted earnings per share o.","evidence_excerpt":"Fourth quarter net sales from continuing operations totaled $173.3 million, a 4.6% decrease from the prior year. For the full-year, net sales from continuing operations decreased 1.6% to $673.3 million. • Fourth quarter diluted earnings per share from continuing operations were $0.24 compared to diluted earnings per share of $0.21 per share a year ago, and fourth quarter adjusted diluted earnings per share from continuing operations were $0.36 compared to $0.45 in the prior year. 2023 full-year diluted loss per share from continuing operations were $0.21 compared to diluted earnings per share of $0.46 in the prior year, and adjusted diluted earnings per share from continuing operations were $1.03 compared to $1.00 in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1606498/000160649824000016/0001606498-24-000016-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full-year 2023"},{"label":"Revenue","value":"Fourth quarter net sales from continuing operations totaled $173.3 million, a 4.6% decrease from the prior year. For the"},{"label":"EPS","value":"Fourth quarter diluted earnings per share from continuing operations were $0.24 compared to diluted earnings per share o"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}